CMC leadership from clinical development to commercial launch.
Ghlobe partners with emerging pharmaceutical companies to build and execute late-stage CMC strategies spanning drug substance, drug product, manufacturing, regulatory readiness, and global supply.
Transform an early clinical program into a registration-ready manufacturing network.
The CMC model that gets a molecule into the clinic is rarely the model that carries it through Phase 3, registration, validation, launch, and commercial supply. Ghlobe specializes in that transition.
Build the foundation
Development strategy, critical risks, analytical control, supply continuity and CDMO operating model.
Scale and industrialize
Process understanding, technology transfer, manufacturing network design and registration strategy.
Establish readiness
Registration batches, validation, stability, comparability, specifications and filing execution.
Operationalize supply
Commercial readiness, launch inventory, supply resilience, governance and lifecycle management.
Senior technical judgment without losing operating detail.
We work across functions and external manufacturing networks to convert development risk into explicit decisions, technical plans, governance, and executable timelines.
